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SHORT COMMUNICATION
Treatment of advanced meduliary thyroid cancer with an alternating
combinaton of 5FU-streptozocin and 5FU-dacarbazine
M Schlumbergerl, N Abdelmoumene', MJ Delisle2, JE Couette3 and the Groupe d'Etude des
Tumeurs 'a Calcitonine (GETC)
'Institut Gustave-Roussy, 9485 VilkeifCedex, France; 2lnstitut Jean Godwot, 51000 Reins, France; 3Institut Fran;ois Baclesse,
14000 Caen, France.
Sm_ry Combnation of 5-fluorouracil (5-FU) and stetozocn and 5-FU and dacarbazie were given
altenatey to 20 patients with mnstatic thyroid ainon Three partial onses and 11
long-term stabilizations were observed. No unexpect toxicity occurred.
K w.rq chamotherapy, medulLary thyroid arcinoma
Medullary thyroid carcinoma (MTC) is a neuroendocrine
tumour which arises from thyroid C-lls. Surgery is the
main treatment when the disease is confined to the neck
(Wahl and Roher, 1988). Extenal irradiation may be
indicated in patients with a dectable cakcitonin level after
an apparently complete surgical procedure (Schlumberger et
al., 1991). Chemotherapy plays no role in the early manage-
ment. This disease usually follows an indolent course even at
the stage of diant spread, and patients with lung or liver
metastases may survive years without systemic treatment. In
a minority ofthese metas patients, chemotherapy may be
indicated for rapidly progrssng distant metaa.
Chemotherapy trials have been imited by the scarcity of
these tumours. Response rates were low with doxorubicin
(Gottlieb and Hill 1975; Husain et al., 1978; Shimaoka et al.,
1985; Hosidn and Harmer, 1987; Droz et al., 1990) and
cisplatin (Hosin and Harmer, 1987; Droz et al., 1990), given
either as single agents or in combination (Shimaoka et al.,
1985; Sridhar et al., 1985; Williams et al., 1986; Droz et al.,
1990). Furthermore, toxcities were siant. A recent trial
(M Schlumberger, unpublished data) with etoposide given as
a single agent did not confirm a previous report (Hoskin and
Harmer, 1987), as no tumour response was observed among
16 evaluable patients. Interferon a2a (Schlumberger et al.,
1991) and somatostatin analogues (Mahler et al., 1990;
Modigii et al., 1992) did not produce any tumour res-
ponse. Therefore, there is a clear need for investigation of
other agents in the treatment of this diseas.
In the present triaL three drugs which have been shown to
be active in other neuroendocrine tumours (Kessinger et al.,
1983) were givn, by alternating a combination of 5-
fluorouracil and streptozocin with a combination of 5-
fluorouracil and dacarbazie. This was further encouraged by
the anecdotal report of the effiacy of 5-fluorouracil and
daarbazine in two MTC patients (Pursson, 1988).
PatiU
From July 1986 to March 1993 20 patients (Table I) with
progressive distant metasa of MTC were entered into this
trial. Their mean age was 47 years (range 26-72). There were
15 males and five femals. Among them, 18 had undergone a
total thyroidectomy with bilateral cervical lymph node dissec-
tion, and 11 had received post-operatively external radio-
therapy to the neck and mdiastinum. Two patients were not
operated on for diffuse distant metastases at presentation.
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Sixteen had been treated with one or more chemotherapeutic
regimens, with drugs such as etoposide (nine patients), mitox-
antrone (three patients), cisplatin (three patients) and doxo-
rubicin (four patients), and all faied to respond.
All patients had measurable metastatic lesions that were
documented by chest radiography, neck or liver ultrasono-
graphy or chest or abdominal computerised tomographic
scan. The tumour markers cakcitonin (CT) and carcinoembry-
onic antigen (CEA) were measured and followed in all
paients but were not accepted as the only response criteria.
The criteria used for reporing responses for measurable
tumour masses were those ofMiler et al. (1981). The tumour
marker response was defined as partial for at least a 50%
reduction, as minimal response between 25 and 50% reduc-
tion, no change, and progression for an increase of at kast
25%.
Patients' eligibility requirements included leucocyte count
greater than 4000i1-l and platelet count greater than
150000pl-', a serum creatinine of 120pmolI-I or less, a
total bilirubin of kss than or equal to 342pmol1-I and no
chemotherapy during the preding 3 months. Informed con-
sent was obtained from all patients.
Treatiw
Before therapy, and also at the time of each evaluation, a
medical history was taken, and the patient underwent
physical examination and tumour measurements. Laboratory
analysis kucocyte count, platelet count, haemo-
globin, a blood chemistry pane, ECG and assays of serm
CT and CEA. Appropriate images were obtained of any
indicator lesions.
Therapy was ni in the hospital. During the first
course, dacarbazine was given at 200mgm2 and 5-FU at
400mgm2, both by intravenous injection daily for 5 days.
Three weeks later, steptozocin was given at 500mgm-2 and
5-FU at 400mgm2, both by intravenous injection daily for
5 days. At 6 weeks, this cyce was repeated. Therapy was
continued until tumour progron or in ca of stable
disease or tumour regrssion, as long as there was no
evidence of srmptomatic or general deterioration or tox-
icity.
The 20 patients entered into this trial were evaluable for
toxicity and for response. Each patient received an average of
five (range 1-9) courses of 5-FU-d and four
(range 1-10) courses of 5-FU-stozocin. Three partialM SctdurTe et al
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tumour responses were observed after one, seven and three
cycles of chemotherapy, and lasted 11, 9 and 8 months
respecuively. In two patients (cases 8 and 14) all tumour sites
responded, whereas in patient 7 a partial response was
observed in skin and liver and a stabilization in lung metas-
tases. Calcitonin level dereased by 52%, 38% and 15%
respecively, and CEA level decreased by 91°% in patient 8,
was stable in patient 14 and increased by 64% in patient 7.
Eleven patients had a stable disease for 4-29 months (mean
12.8 months): the performance status improved in seven of
these patients, remained unchanged in three and worsened in
patient 20. Nine ofthese 11 patients with a stable disease had
previously been treated with other drug regimens and none
of them responded. Six patients had progressive disease.
Nausea and vomiting were limited by antiemetic drugs and
digestive toxicity was observed in four patients (grade 2 in
two and grade 3 in two patients). One patient had a stoma-
titis (grade 2). Alopecia (grade 2) was observed in two
patients, renal toxicity (grade 2 and 3) in two, cardiac tox-
icity (grade 3) in two and hepatic toxicity (grade 2) in one
patient. No myelotoxicity or infection was observed.
The indication for systemic cytotoxic chemotherapy treat-
ment in MTC patients was rapidly progressive disease. In
such patients, the actual response rate is unknown. Doxo-
rubicin has been the most frequently reported agent with a
response rate probably not higher than 15-20%, all res-
ponses being partial and transient and with high toxicities.
Combination of doxorubicn with other drugs such as cis-
platin (Shimaoka et al., 1985; Sridhar et al., 1985; Williams
et al., 1986; Droz et al., 1990), or streptozocin (Kelson et al.,
1982) did not increase the response rate.
Responses to this combined regimen compared favourably
with other therapeutic trials in patients with metastatic
meduflary thyroid carcinoma in terms of both response rate
and of toxicity (Wu et al., 1994). In fact, three patients
achieved a partial response and 11 other patients a stabiliza-
tion, with an improvement in performance status in seven,
for long periods of time. Of note, this regimen may be
effective with an acceptable toxicity even in patients who had
already been treated with other drug regimens. Response to
therapy may be rapid or may occur after several courses of
chemotherapy, in accordance with the slow growth rate of
most of these tumours.
Therefore, this study demonstrates clearly that, at least in
some patients, this combination is effective, and favours new
therapeutic trials using other combination regimens with
these drugs.
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